NIDDK/NIAID/NICHD/NCCAM Type 1 Diabetes TrialNet: Clinical Centers Grant

Opportunity ID: 44517

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-DK-08-011
Funding Opportunity Title: Type 1 Diabetes TrialNet: Clinical Centers (U01)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Food and Nutrition
Health
Income Security and Social Services
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.213 — Research and Training in Complementary and Alternative Medicine
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Dec 24, 2008
Last Updated Date:
Original Closing Date for Applications: Mar 10, 2009
Current Closing Date for Applications: Mar 10, 2009
Archive Date: Apr 10, 2009
Estimated Total Program Funding: $5,400,000
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: Others (see text field entitled “Additional Information on Eligibility” for clarification)
Private institutions of higher education
Public and State controlled institutions of higher education
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Non-domestic (non-U.S.) Entities (Foreign Organizations); Tribally Controlled Colleges and Universities (TCCUs) .

Additional Information

Agency Name: National Institutes of Health
Description: Purpose. This FOA is being issued by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institute of Allergy and Infectious Diseases (NIAID), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and the National Center for Complementary and Alternative Medicine (NCCAM) to solicit applications to support clinical centers which will participate in studies aimed at preventing or delaying the onset or progression of type 1 diabetes (T1D) as part of the TrialNet clinical research network. TrialNet is working to achieve its goals through improving understanding of the natural history of the disease, screening and identifying persons at risk, and conducting clinical trials to evaluate promising new therapies that interdict the disease process. Most importantly, TrialNet evaluates new therapies, especially immunotherapies, in individuals (including children) who do not yet have clinical disease. To support the goal of prevention, TrialNet also performs studies that generate safety and efficacy information in individuals with newly-diagnosed diabetes. TrialNet tests interventions in patients with recent onset T1D to decrease b-cell destruction and/or enhance b-cell survival or regeneration in persons with T1D and residual b-cell function. In addition, TrialNet also evaluates methodologies to enhance the conduct of its clinical trials, which include tests of outcome assessment methodology, the evaluation of surrogate markers, and mechanistic studies (studies to understand underlying pathophysiology) laying the foundation for future clinical trials.
Link to Additional Information: http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-08-011.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV

Email:FBOWebmaster@OD.NIH.GOV

Version History

Version Modification Description Updated Date

Related Documents

Packages


Comments

Leave a Reply

Your email address will not be published. Required fields are marked *